Your browser doesn't support javascript.
loading
Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
Stok, Colin; Kok, Yannick P; van den Tempel, Nathalie; van Vugt, Marcel A T M.
Afiliação
  • Stok C; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
  • Kok YP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
  • van den Tempel N; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
  • van Vugt MATM; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
Nucleic Acids Res ; 49(8): 4239-4257, 2021 05 07.
Article em En | MEDLINE | ID: mdl-33744950
ABSTRACT
Tumours with mutations in the BRCA1/BRCA2 genes have impaired double-stranded DNA break repair, compromised replication fork protection and increased sensitivity to replication blocking agents, a phenotype collectively known as 'BRCAness'. Tumours with a BRCAness phenotype become dependent on alternative repair pathways that are error-prone and introduce specific patterns of somatic mutations across the genome. The increasing availability of next-generation sequencing data of tumour samples has enabled identification of distinct mutational signatures associated with BRCAness. These signatures reveal that alternative repair pathways, including Polymerase θ-mediated alternative end-joining and RAD52-mediated single strand annealing are active in BRCA1/2-deficient tumours, pointing towards potential therapeutic targets in these tumours. Additionally, insight into the mutations and consequences of unrepaired DNA lesions may also aid in the identification of BRCA-like tumours lacking BRCA1/BRCA2 gene inactivation. This is clinically relevant, as these tumours respond favourably to treatment with DNA-damaging agents, including PARP inhibitors or cisplatin, which have been successfully used to treat patients with BRCA1/2-defective tumours. In this review, we aim to provide insight in the origins of the mutational landscape associated with BRCAness by exploring the molecular biology of alternative DNA repair pathways, which may represent actionable therapeutic targets in in these cells.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína BRCA1 / Proteína BRCA2 / Reparo do DNA / Quebras de DNA de Cadeia Dupla / Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína BRCA1 / Proteína BRCA2 / Reparo do DNA / Quebras de DNA de Cadeia Dupla / Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article